Biotech News

Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026

ACADIA Pharmaceuticals Inc. (ACAD)ACADIA Pharmaceuticals Inc.2026-07-15 20:05 ESTFDA / regulatory

Home

News & Media

News Releases

Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026

July 15, 2026

General

Company to host conference call and webcast on Tuesday, August 4, 2026, at 4:30 p.m. Eastern Time

SAN DIEGO—(BUSINESS WIRE)— Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 4, 2026, at 4:30 p.m. Eastern Time.

The conference call will be available on Acadia’s website, acadia.com under the investors section and will be archived for approximately 90 days. The conference call may also be accessed by registering for the call here . Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.

About Acadia Pharmaceuticals

Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X .

Source: Acadia Pharmaceuticals Inc.

Open original release

Related news

ACADACADIA Pharmaceuticals Inc.2026-07-06 13:04 EST

Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer

ACADACADIA Pharmaceuticals Inc.2026-06-26 10:49 EST

DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP

ACADACADIA Pharmaceuticals Inc.2026-05-06 20:05 EST

Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

ACADACADIA Pharmaceuticals Inc.2026-04-30 20:05 EST

Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career

ACADACADIA Pharmaceuticals Inc.2026-04-28 12:00 EST

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

ACADACADIA Pharmaceuticals Inc.2024-10-16 20:07 EST

News Releases

MORMorphoSys2026-07-17 12:00 EST

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

INBXInhibrx2026-07-16 13:00 EST

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million

ARTLArtelo Biosciences2026-07-16 12:48 EST

Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions

MRKMerck2026-07-16 12:31 EST

Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

Stock data

Close
25.92 USD
Market cap
4.49B USD
Exchange
NASDAQ
Sector
Biotechnology
Location
United States